A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment

Published 2017 View Full Article

Authors

Keywords

obinutuzumab; rituximab; Burkitt lymphoma; proteomics; resistant

Journal

Oncotarget

Volume 8, Issue 69, Pages -

Publisher

Impact Journals, LLC

Online

2017-12-09

DOI

10.18632/oncotarget.23040

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started